ArticlePharmaceuticals (Basel, Switzerland)2022
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors.
Open access · goldAbstract read
In one paragraph
Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Opioid Add-On Combination Therapy for Cancer Pain: Pharmacological Rationale, Clinical Evidence, and Future Directions.CNS drugs · 2026Review
- Bioisostere-Driven Discovery of SePP: A Selenium-Containing Polypharmacological Agent Relevant to Fragile X Syndrome.Journal of medicinal chemistry · 2026Article
- New advances in small molecule drugs targeting NMDA receptors.Acta pharmacologica Sinica · 2026Review
- The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine.Molecular psychiatry · 2025Review
- New Synthesis and Pharmacological Evaluation of Enantiomerically Pure (Journal of medicinal chemistry · 2025Article
- Demystifying the Antidepressant Mechanism of Action of Stinels, a Novel Class of Neuroplastogens: Positive Allosteric Modulators of the NMDA Receptor.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'.Molecular psychiatry · 2024Article
- N-methyl-D-aspartate Receptors and Depression: Linking Psychopharmacology, Pathology and Physiology in a Unifying Hypothesis for the Epigenetic Code of Neural Plasticity.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Hyperglycemia impairs EAAT2 glutamate transporter trafficking and glutamate clearance in islets of Langerhans: implications for type 2 diabetes pathogenesis and treatment.American journal of physiology. Endocrinology and metabolism · 2024Article
- Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment.Drugs in R&D · 2024Article
- GM-1020: a novel, orally bioavailable NMDA receptor antagonist with rapid and robust antidepressant-like effects at well-tolerated doses in rodents.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism.Drugs in R&D · 2024Article
- Major depressive disorder: hypothesis, mechanism, prevention and treatment.Signal transduction and targeted therapy · 2024Review
- Ketamine in neuropsychiatric disorders: an update.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Sex-dependent effects of the uncompetitive N-methyl-D-aspartate receptor antagonist REL-1017 in G93A-SOD1 amyotrophic lateral sclerosis mice.Frontiers in neurology · 2024Article
- Article
- Esmethadone-HCl (REL-1017): a promising rapid antidepressant.European archives of psychiatry and clinical neuroscience · 2023Review
- Rapid onset brain plasticity at novel pharmacologic targets hypothetically drives innovations for rapid onset antidepressant actions.Journal of psychopharmacology (Oxford, England) · 2023Article
- Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 9 institutions in 3 countries.
Ezio BettiniIn Vitro Pharmacology Department, Aptuit, An Evotec Company, 37135 Verona, Italy.
Stephen M StahlDepartment of Psychiatry, VAMC (SD), University of California, San Diego, CA 92093, USA.
Sara De MartinDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122 Padua, Italy.ORCID 0000-0001-6398-8237
Andrea MattareiDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122 Padua, Italy.ORCID 0000-0002-2023-0749
Jacopo SgrignaniInstitute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), 6500 Bellinzona, Switzerland.ORCID 0000-0002-8633-1032
Corrado CarignaniIn Vitro Pharmacology Department, Aptuit, An Evotec Company, 37135 Verona, Italy.
Selena NolaIn Vitro Pharmacology Department, Aptuit, An Evotec Company, 37135 Verona, Italy.
Patrizia LocatelliInstitute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), 6500 Bellinzona, Switzerland.
Marco PappagalloDepartment of Anesthesiology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Charles E InturrisiRelmada Therapeutics, Coral Gables, FL 33134, USA.
Francesco BifariDepartment of Medical Biotechnology and Translational Medicine, University of Milan, 20122 Milan, Italy.ORCID 0000-0003-2028-3012
Andrea CavalliInstitute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), 6500 Bellinzona, Switzerland.
Andrea AlimontiDepartment of Health Sciences and Technology, ETH Zurich, 8092 Zurich, Switzerland.
Luca PaniRelmada Therapeutics, Coral Gables, FL 33134, USA.ORCID 0000-0001-9273-2839
Maurizio FavaDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA.
Sergio TraversaRelmada Therapeutics, Coral Gables, FL 33134, USA.
Franco FolliDepartment of Health Sciences, University of Milan, 20122 Milan, Italy.
Paolo L ManfrediRelmada Therapeutics, Coral Gables, FL 33134, USA.
Aptuit (Italy) · ITUniversity of Padua · ITUniversità della Svizzera italiana · CHUniversity of Milan · ITAlbert Einstein College of Medicine · USMassachusetts General Hospital · USSIB Swiss Institute of Bioinformatics · CHUniversity of California San Diego · USUniversity of Modena and Reggio Emilia · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excessive Ca
Indexed as
dextromethadonedextromethorphand-methadoneesmethadone HCLketaminemajor depressive disorder (MDD)memantineMK-801N-methyl-D-aspartate receptor (NMDAR)REL-1017
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.